Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function
A considerable number of patients with central precocious puberty (CPP) treated with depot GnRH agonists have reached final height (FH). The aim of this prospective, multicentric study was the evaluation of the benefits, side-effects, and long term outcome of depot GnRH agonist therapy. We investiga...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical endocrinology and metabolism 1999-12, Vol.84 (12), p.4583-4590 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4590 |
|---|---|
| container_issue | 12 |
| container_start_page | 4583 |
| container_title | The journal of clinical endocrinology and metabolism |
| container_volume | 84 |
| creator | HEGER, S PARTSCH, C.-J SIPPELL, W. G |
| description | A considerable number of patients with central precocious puberty (CPP) treated with depot GnRH agonists have reached final height (FH). The aim of this prospective, multicentric study was the evaluation of the benefits, side-effects, and long term outcome of depot GnRH agonist therapy. We investigated 50 young women (mean +/- SD age, 16.7+/-2.6 yr; range, 12.9-23.4 yr) at FH. They received depot triptorelin over a period of 4.4+/-2.1 yr (range, 1.0-9.7 yr). Target height (TH) and predicted adult height (PAH) at the start of treatment were 163.6+/-6.2 and 154.9+/-9.6 cm, respectively (P < 0.05). FH was 160.6+/-8.0 cm (FH vs. TH, P = NS; FH vs. PAH, P < 0.05). Young patients showed the highest height gain (FH minus initial PAH). Seventy-eight percent of all patients reached a FH within their TH range. Even in young patients and those with an unfavorable initial PAH below the TH range, 60% reached a FH within their individual TH range. Standardized bone mineral density and standardized bone mineral density SD score investigated by dual energy x-ray absorptiometry of the lumbar spine (L1-L4) were 1040.9+/-124.2 mg/cm2 and 0.0+/-1.0; those of the femoral neck were 902.2+/-115.4 mg/cm2 and 0.2+/-1.0, respectively. The SD score of the ratio of sitting height over lower leg length was normal (0.3+/-1.2). Body mass index SD scores at pretreatment, at the end of treatment, and at FH were not significantly different (2.0+/-2.0, 2.0+/-2.0, and 1.7+/-2.2, respectively). Menarche or remenarche started at age 12.3+/-1.4 yr (range, 9.3-15.8 yr) in all patients. In conclusion, long term depot GnRH agonist treatment of CPP girls preserved genetic height potential and improved FH significantly combined with normal body proportions. No negative effect on bone mineral density and reproductive function was seen. Treatment neither caused nor aggravated obesity. |
| doi_str_mv | 10.1210/jc.84.12.4583 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69361673</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17665100</sourcerecordid><originalsourceid>FETCH-LOGICAL-c264t-4c76a0ee48c4ee1bfd4e97f51cb91768291f38b118e579b1fe4dbe644ee6ff2f3</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoO4uOPq0avkIJ62Z5NO-svbsrgqDOxlBW9NOqnMZOhO2iQtzK_0L1nNDOjNU1XeeuqtCkXIO862vOTs7qi3rcR0K6tWvCAb3smqaHjXvCQbxkpedE3545q8TunIGJeyEq_INWdVh7rYkN-74PdFhjjRsGQdJqDK4pMamEOm--CVCTmG2fkiwggqOb-nhxCn4BHFukuZ5ggqT-AzDZZqjFGNdI6gg3ZhSXReBoj59Ik-Oo-VA7j9Id_SIZgTYmEOMbvg00XBLeaQ3CqtCs6ZnIfV0oBH_XRLlTc0AraaRWf3C6hdvF4b3pArq8YEby_xhnx__Pz88LXYPX359nC_K3RZy1xI3dSKAchWSwA-WCOha2zF9dDxpm7LjlvRDpy3UDXdwC1IM0AtEa6tLa24IR_PvrjDzwVS7ieXNIyj8oA_7utO1LxuxH9BnFZXnDEEizOoY0gpgu3n6CYVTz1n_Xrq_qj7VmLar6dG_v3FeBkmMP_Q59si8OECqKTVaKPy2qW_XFkyUZXiDy39uH4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17665100</pqid></control><display><type>article</type><title>Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>HEGER, S ; PARTSCH, C.-J ; SIPPELL, W. G</creator><creatorcontrib>HEGER, S ; PARTSCH, C.-J ; SIPPELL, W. G</creatorcontrib><description>A considerable number of patients with central precocious puberty (CPP) treated with depot GnRH agonists have reached final height (FH). The aim of this prospective, multicentric study was the evaluation of the benefits, side-effects, and long term outcome of depot GnRH agonist therapy. We investigated 50 young women (mean +/- SD age, 16.7+/-2.6 yr; range, 12.9-23.4 yr) at FH. They received depot triptorelin over a period of 4.4+/-2.1 yr (range, 1.0-9.7 yr). Target height (TH) and predicted adult height (PAH) at the start of treatment were 163.6+/-6.2 and 154.9+/-9.6 cm, respectively (P < 0.05). FH was 160.6+/-8.0 cm (FH vs. TH, P = NS; FH vs. PAH, P < 0.05). Young patients showed the highest height gain (FH minus initial PAH). Seventy-eight percent of all patients reached a FH within their TH range. Even in young patients and those with an unfavorable initial PAH below the TH range, 60% reached a FH within their individual TH range. Standardized bone mineral density and standardized bone mineral density SD score investigated by dual energy x-ray absorptiometry of the lumbar spine (L1-L4) were 1040.9+/-124.2 mg/cm2 and 0.0+/-1.0; those of the femoral neck were 902.2+/-115.4 mg/cm2 and 0.2+/-1.0, respectively. The SD score of the ratio of sitting height over lower leg length was normal (0.3+/-1.2). Body mass index SD scores at pretreatment, at the end of treatment, and at FH were not significantly different (2.0+/-2.0, 2.0+/-2.0, and 1.7+/-2.2, respectively). Menarche or remenarche started at age 12.3+/-1.4 yr (range, 9.3-15.8 yr) in all patients. In conclusion, long term depot GnRH agonist treatment of CPP girls preserved genetic height potential and improved FH significantly combined with normal body proportions. No negative effect on bone mineral density and reproductive function was seen. Treatment neither caused nor aggravated obesity.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.84.12.4583</identifier><identifier>PMID: 10599723</identifier><identifier>CODEN: JCEMAZ</identifier><language>eng</language><publisher>Bethesda, MD: Endocrine Society</publisher><subject>Absorptiometry, Photon ; Adolescent ; Adult ; Biological and medical sciences ; Body Composition ; Body Constitution ; Body Height ; Bone Density ; Child ; Delayed-Action Preparations ; Female ; Genital system. Reproduction ; Humans ; Medical sciences ; Menarche ; Pharmacology. Drug treatments ; Puberty, Precocious - drug therapy ; Reproduction ; Treatment Outcome ; Triptorelin Pamoate - administration & dosage ; Triptorelin Pamoate - therapeutic use</subject><ispartof>The journal of clinical endocrinology and metabolism, 1999-12, Vol.84 (12), p.4583-4590</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c264t-4c76a0ee48c4ee1bfd4e97f51cb91768291f38b118e579b1fe4dbe644ee6ff2f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1220352$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10599723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HEGER, S</creatorcontrib><creatorcontrib>PARTSCH, C.-J</creatorcontrib><creatorcontrib>SIPPELL, W. G</creatorcontrib><title>Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>A considerable number of patients with central precocious puberty (CPP) treated with depot GnRH agonists have reached final height (FH). The aim of this prospective, multicentric study was the evaluation of the benefits, side-effects, and long term outcome of depot GnRH agonist therapy. We investigated 50 young women (mean +/- SD age, 16.7+/-2.6 yr; range, 12.9-23.4 yr) at FH. They received depot triptorelin over a period of 4.4+/-2.1 yr (range, 1.0-9.7 yr). Target height (TH) and predicted adult height (PAH) at the start of treatment were 163.6+/-6.2 and 154.9+/-9.6 cm, respectively (P < 0.05). FH was 160.6+/-8.0 cm (FH vs. TH, P = NS; FH vs. PAH, P < 0.05). Young patients showed the highest height gain (FH minus initial PAH). Seventy-eight percent of all patients reached a FH within their TH range. Even in young patients and those with an unfavorable initial PAH below the TH range, 60% reached a FH within their individual TH range. Standardized bone mineral density and standardized bone mineral density SD score investigated by dual energy x-ray absorptiometry of the lumbar spine (L1-L4) were 1040.9+/-124.2 mg/cm2 and 0.0+/-1.0; those of the femoral neck were 902.2+/-115.4 mg/cm2 and 0.2+/-1.0, respectively. The SD score of the ratio of sitting height over lower leg length was normal (0.3+/-1.2). Body mass index SD scores at pretreatment, at the end of treatment, and at FH were not significantly different (2.0+/-2.0, 2.0+/-2.0, and 1.7+/-2.2, respectively). Menarche or remenarche started at age 12.3+/-1.4 yr (range, 9.3-15.8 yr) in all patients. In conclusion, long term depot GnRH agonist treatment of CPP girls preserved genetic height potential and improved FH significantly combined with normal body proportions. No negative effect on bone mineral density and reproductive function was seen. Treatment neither caused nor aggravated obesity.</description><subject>Absorptiometry, Photon</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Body Composition</subject><subject>Body Constitution</subject><subject>Body Height</subject><subject>Bone Density</subject><subject>Child</subject><subject>Delayed-Action Preparations</subject><subject>Female</subject><subject>Genital system. Reproduction</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Menarche</subject><subject>Pharmacology. Drug treatments</subject><subject>Puberty, Precocious - drug therapy</subject><subject>Reproduction</subject><subject>Treatment Outcome</subject><subject>Triptorelin Pamoate - administration & dosage</subject><subject>Triptorelin Pamoate - therapeutic use</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2LFDEQhoO4uOPq0avkIJ62Z5NO-svbsrgqDOxlBW9NOqnMZOhO2iQtzK_0L1nNDOjNU1XeeuqtCkXIO862vOTs7qi3rcR0K6tWvCAb3smqaHjXvCQbxkpedE3545q8TunIGJeyEq_INWdVh7rYkN-74PdFhjjRsGQdJqDK4pMamEOm--CVCTmG2fkiwggqOb-nhxCn4BHFukuZ5ggqT-AzDZZqjFGNdI6gg3ZhSXReBoj59Ik-Oo-VA7j9Id_SIZgTYmEOMbvg00XBLeaQ3CqtCs6ZnIfV0oBH_XRLlTc0AraaRWf3C6hdvF4b3pArq8YEby_xhnx__Pz88LXYPX359nC_K3RZy1xI3dSKAchWSwA-WCOha2zF9dDxpm7LjlvRDpy3UDXdwC1IM0AtEa6tLa24IR_PvrjDzwVS7ieXNIyj8oA_7utO1LxuxH9BnFZXnDEEizOoY0gpgu3n6CYVTz1n_Xrq_qj7VmLar6dG_v3FeBkmMP_Q59si8OECqKTVaKPy2qW_XFkyUZXiDy39uH4</recordid><startdate>199912</startdate><enddate>199912</enddate><creator>HEGER, S</creator><creator>PARTSCH, C.-J</creator><creator>SIPPELL, W. G</creator><general>Endocrine Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>199912</creationdate><title>Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function</title><author>HEGER, S ; PARTSCH, C.-J ; SIPPELL, W. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c264t-4c76a0ee48c4ee1bfd4e97f51cb91768291f38b118e579b1fe4dbe644ee6ff2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Absorptiometry, Photon</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Body Composition</topic><topic>Body Constitution</topic><topic>Body Height</topic><topic>Bone Density</topic><topic>Child</topic><topic>Delayed-Action Preparations</topic><topic>Female</topic><topic>Genital system. Reproduction</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Menarche</topic><topic>Pharmacology. Drug treatments</topic><topic>Puberty, Precocious - drug therapy</topic><topic>Reproduction</topic><topic>Treatment Outcome</topic><topic>Triptorelin Pamoate - administration & dosage</topic><topic>Triptorelin Pamoate - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HEGER, S</creatorcontrib><creatorcontrib>PARTSCH, C.-J</creatorcontrib><creatorcontrib>SIPPELL, W. G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HEGER, S</au><au>PARTSCH, C.-J</au><au>SIPPELL, W. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>1999-12</date><risdate>1999</risdate><volume>84</volume><issue>12</issue><spage>4583</spage><epage>4590</epage><pages>4583-4590</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><coden>JCEMAZ</coden><abstract>A considerable number of patients with central precocious puberty (CPP) treated with depot GnRH agonists have reached final height (FH). The aim of this prospective, multicentric study was the evaluation of the benefits, side-effects, and long term outcome of depot GnRH agonist therapy. We investigated 50 young women (mean +/- SD age, 16.7+/-2.6 yr; range, 12.9-23.4 yr) at FH. They received depot triptorelin over a period of 4.4+/-2.1 yr (range, 1.0-9.7 yr). Target height (TH) and predicted adult height (PAH) at the start of treatment were 163.6+/-6.2 and 154.9+/-9.6 cm, respectively (P < 0.05). FH was 160.6+/-8.0 cm (FH vs. TH, P = NS; FH vs. PAH, P < 0.05). Young patients showed the highest height gain (FH minus initial PAH). Seventy-eight percent of all patients reached a FH within their TH range. Even in young patients and those with an unfavorable initial PAH below the TH range, 60% reached a FH within their individual TH range. Standardized bone mineral density and standardized bone mineral density SD score investigated by dual energy x-ray absorptiometry of the lumbar spine (L1-L4) were 1040.9+/-124.2 mg/cm2 and 0.0+/-1.0; those of the femoral neck were 902.2+/-115.4 mg/cm2 and 0.2+/-1.0, respectively. The SD score of the ratio of sitting height over lower leg length was normal (0.3+/-1.2). Body mass index SD scores at pretreatment, at the end of treatment, and at FH were not significantly different (2.0+/-2.0, 2.0+/-2.0, and 1.7+/-2.2, respectively). Menarche or remenarche started at age 12.3+/-1.4 yr (range, 9.3-15.8 yr) in all patients. In conclusion, long term depot GnRH agonist treatment of CPP girls preserved genetic height potential and improved FH significantly combined with normal body proportions. No negative effect on bone mineral density and reproductive function was seen. Treatment neither caused nor aggravated obesity.</abstract><cop>Bethesda, MD</cop><pub>Endocrine Society</pub><pmid>10599723</pmid><doi>10.1210/jc.84.12.4583</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-972X |
| ispartof | The journal of clinical endocrinology and metabolism, 1999-12, Vol.84 (12), p.4583-4590 |
| issn | 0021-972X 1945-7197 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69361673 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Absorptiometry, Photon Adolescent Adult Biological and medical sciences Body Composition Body Constitution Body Height Bone Density Child Delayed-Action Preparations Female Genital system. Reproduction Humans Medical sciences Menarche Pharmacology. Drug treatments Puberty, Precocious - drug therapy Reproduction Treatment Outcome Triptorelin Pamoate - administration & dosage Triptorelin Pamoate - therapeutic use |
| title | Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T08%3A37%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20outcome%20after%20depot%20gonadotropin-releasing%20hormone%20agonist%20treatment%20of%20central%20precocious%20puberty:%20Final%20height,%20body%20proportions,%20body%20composition,%20bone%20mineral%20density,%20and%20reproductive%20function&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=HEGER,%20S&rft.date=1999-12&rft.volume=84&rft.issue=12&rft.spage=4583&rft.epage=4590&rft.pages=4583-4590&rft.issn=0021-972X&rft.eissn=1945-7197&rft.coden=JCEMAZ&rft_id=info:doi/10.1210/jc.84.12.4583&rft_dat=%3Cproquest_cross%3E17665100%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17665100&rft_id=info:pmid/10599723&rfr_iscdi=true |